Merck KGaA (XTRA:MRK) is back in focus after the U.S. FDA accepted its new drug application for pimicotinib, supported by ...

Merck MRK continues to face persistent challenges with sales of its second-largest product, Gardasil, which is a vaccine used ...

A meaningful portion of Merck’s MRK revenues comes from its oncology franchise anchored by its blockbuster PD-L1 inhibitor, ...

Merck & Co. Inc. (NYSE:MRK) ranks among the best long-term stocks to buy according to D. E. Shaw. On October 30, Merck & Co. Inc. (NYSE:MRK) announced its Q3 2025 earnings, showing ...

AbbVie extended the patent life on Humira for years, enough time to more than replace the sales. Now Merck and Bristol Myers ...

Merck’s MRK stock has risen 32.3% in the past three months. The stock has also been trading above its 50-day and 200-day ...

new video loaded: Merck earnings beat estimates, raises full year guidance Merck posted better than expected sales and profit. The company getting a boost from its diabetes drug Januvia, but strong ...

Merck KGaA reported third-quarter earnings with 5.2% organic sales growth, and the adjusted EBITDA margin increased by 70 basis points to 31.4%. Management confirmed its full-year outlook, while ...

If you are wondering whether Merck's current share price reflects its true worth, this article walks through what the numbers ...

The latest update to the Merck stock story centers on a revised price target, reflecting how analysts are reassessing the ...

Merck (MRK) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the stock. Over the ...

Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $113.3, a high estimate of $130.00, and a low estimate of $95.00. This current ...